U.S. Next Generation Diabetes Therapy and Drug Delivery Market generated $446 million in 2015 and is anticipated to garner $6,510 Million by 2023, growing at a CAGR of 33.0% during the forecast period, 2017-2023.
Increase in prevalence of diabetes, surge in disposable income, rise in healthcare expenditure, and the advantages of adopting next generation diabetes products over conventional ones drive the growth of the U.S. next generation diabetes therapy and drug delivery market. Additionally, developing products with fewer side effects at affordable prices and the high undiagnosed diabetes patient population provide lucrative opportunities to emerging market players. However, high cost and less variability of products along with a lack of awareness hamper market growth.
Get Sample Copy of Report @ https://www.alliedmarketresearch.com/request-sample/4621
The report segments the U.S. next generation diabetes therapy and drug delivery market by product type, demographic, indication, and end user. Based on product type, the market is fragmented into inhalable insulin, oral insulin, insulin patch, CGM system, and artificial pancreas. The CGM system segment generated the highest revenue in 2016, owing to the high adoption rate of CGM devices as a large number of them are FDA approved. Based on demographic, the report bifurcates the market into adult population (>14 years) and child population (<14 years). The adult population segment dominated the market in 2016 and is expected to grow at a significant rate in the future, as almost 90% of the diabetic population in U.S. are above the age of 18 years.
The market is further bifurcated into type I and type II diabetes based on indication, with the type II diabetes segment expected to grow at the fastest rate, registering a CAGR of 33.1% during the forecast period. Based on end user, the market is categorized into diagnostics/clinic, ICU, and home healthcare. The diagnostics/clinics segment generated the highest revenue in 2016 and is projected to continue its dominance from 2017 to 2023, owing to an increase in procurement of the products from diagnostics and clinics by diabetic patients. Meanwhile, the home healthcare segment is poised to grow at the highest rate through 2023.
Top Key Players :
- Abbott Laboratories
- Echo Therapeutics Inc.
- Hoffmann-La Roche Ltd.
- GlySens Incorporated
- Medtronic Plc
- Sanofi
- Novo Nordisk
- MannKind Corporation
- Dexcom Inc.
- Senseonics Holding
They have adopted various strategies such as mergers & acquisitions, collaborations, partnerships, and others to gain a strong position in the industry.
Send Enquiry On Report @ https://www.alliedmarketresearch.com/purchase-enquiry/4621
About us:
Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.
Contact:
Sona Padman
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com
